LHC Group, Inc. (NASDAQ:LHCG) Shares Sold by Versant Capital Management Inc

Versant Capital Management Inc decreased its holdings in shares of LHC Group, Inc. (NASDAQ:LHCG) by 52.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 274 shares of the health services provider’s stock after selling 298 shares during the period. Versant Capital Management Inc’s holdings in LHC Group were worth $32,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Parallel Advisors LLC increased its position in LHC Group by 790.0% during the 1st quarter. Parallel Advisors LLC now owns 267 shares of the health services provider’s stock worth $30,000 after purchasing an additional 237 shares during the period. Sageworth Trust Co acquired a new position in LHC Group during the 1st quarter worth approximately $36,000. Quadrant Capital Group LLC increased its position in LHC Group by 1,045.7% during the 1st quarter. Quadrant Capital Group LLC now owns 527 shares of the health services provider’s stock worth $57,000 after purchasing an additional 481 shares during the period. Meeder Asset Management Inc. acquired a new position in LHC Group during the 1st quarter worth approximately $68,000. Finally, Private Capital Group LLC increased its position in LHC Group by 24.4% during the 1st quarter. Private Capital Group LLC now owns 1,116 shares of the health services provider’s stock worth $124,000 after purchasing an additional 219 shares during the period. Institutional investors own 91.59% of the company’s stock.

Several equities analysts have issued reports on LHCG shares. BidaskClub upgraded LHC Group from a “buy” rating to a “strong-buy” rating in a research report on Friday. Royal Bank of Canada boosted their target price on LHC Group to $130.00 and gave the stock an “outperform” rating in a research report on Monday, May 13th. UBS Group set a $133.00 target price on LHC Group and gave the stock a “buy” rating in a research report on Friday, May 10th. Jefferies Financial Group boosted their target price on LHC Group from $125.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, Barclays reiterated a “hold” rating on shares of LHC Group in a research report on Sunday, May 12th. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $120.58.

Shares of LHCG traded down $0.40 on Friday, reaching $123.11. The stock had a trading volume of 4,214 shares, compared to its average volume of 214,467. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of 34.49, a PEG ratio of 2.15 and a beta of 0.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.57 and a quick ratio of 1.57. The company’s 50-day moving average is $120.71. LHC Group, Inc. has a twelve month low of $80.84 and a twelve month high of $129.37.

LHC Group (NASDAQ:LHCG) last released its quarterly earnings results on Wednesday, May 8th. The health services provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.08. The business had revenue of $502.59 million for the quarter, compared to analysts’ expectations of $511.16 million. LHC Group had a return on equity of 8.43% and a net margin of 3.83%. As a group, equities analysts anticipate that LHC Group, Inc. will post 4.3 EPS for the current year.

In related news, Director Ronald T. Nixon sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $117.20, for a total value of $1,406,400.00. Following the sale, the director now owns 29,100 shares in the company, valued at approximately $3,410,520. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John L. Indest sold 30,515 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $113.76, for a total value of $3,471,386.40. Following the completion of the sale, the director now owns 22,947 shares in the company, valued at approximately $2,610,450.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,269 shares of company stock worth $5,314,613. Insiders own 5.20% of the company’s stock.

LHC Group Profile

LHC Group, Inc provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Home & Community-Based Services, Facility-Based Services and Healthcare Innovations.

See Also: Insider Trading – What You Need to Know

Want to see what other hedge funds are holding LHCG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LHC Group, Inc. (NASDAQ:LHCG).

Institutional Ownership by Quarter for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.